2024-11-19 15:20:24
CStone's Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer
Corporate/ 2023-07-23
CStone's Partner Blueprint Medicine...

SUZHOU,China,Dec. 10,2020-- The partner of CStone Pharmaceuticals ("CStone",HKEX: 2616),Blueprint Medicines,announced on December ...

PharmAbcine presents the latest data of the ongoing Phase Ib mTNBC trial at SABCS 2020
Corporate/ 2023-07-23
PharmAbcine presents the latest data of ...

DAEJEON,South Korea,Dec. 9,2020-- PharmAbcine Inc. (KOSDAQ: 208340ks),a clinical-stage biotech company focusing on the development of fully ...

CUSMail

CusMail provide the Latest News , Business and Technology News Release service. Most of our news is paid for distribution to meet global marketing needs. We can provide you with global market support.

© CUSMAIL. All Rights Reserved. Operate by Paid Release